Abstract
Toll-like receptors (TLRs) are a large family of proteins that are expressed in immune cells and various tumor cells. TLR7/8 are located in the intracellular endosomes, participate in tumor immune surveillance and play different roles in tumor growth. Activation of TLRs 7 and 8 triggers induction of a Th1 type innate immune response in the highly sophisticated process of innate immunity signaling with the recent research advances involving the small molecule activation of TLR 7 and 8. The wide range of expression and clinical significance of TLR7/TLR8 in different kinds of cancers have been extensively explored. TLR7/TLR8 can be used as novel diagnostic biomarkers, progression and prognostic indicators, and immunotherapeutic targets for various tumors. Although the mechanism of action of TLR7/8 in cancer immunotherapy is still incomplete, TLRs on T cells are involved in the regulation of T cell function and serve as co-stimulatory molecules and activate T cell immunity. TLR agonists can activate T cell-mediated antitumor responses with both innate and adaptive immune responses to improve tumor therapy. Recently, novel drugs of TLR7 or TLR8 agonists with different scaffolds have been developed. These agonists lead to the induction of certain cytokines and chemokines that can be applied to the treatment of some diseases and can be used as good adjutants for vaccines. Furthermore, TLR7/8 agonists as potential therapeutics for tumor-targeted immunotherapy have been developed. In this review, we summarize the recent advances in the development of immunotherapy strategies targeting TLR7/8 in patients with various cancers and chronic hepatitis B.
Similar content being viewed by others
Introduction
Toll-like receptors (TLRs) are a large family of proteins and a class of pattern recognition receptors, which are not only expressed in immune cells, but also in various tumor cells. As the key components, TLRs are evolutionarily conserved innate immune molecules that play an important part in the innate immune system and promote adaptive immune responses as a bridge between innate immunity and adaptive immunity. Different TLRs are expressed differently in different target cells and play different functions by activating different immune cascades [1]. There are ten kinds of TLRs in the human (TLR1-TLR10) and 13 kinds of TLRs in mice. TLR1, TLR2, TLR4, TLR5, TLR6, TLR10, and TLR11 are receptors located on the surface of the cell membrane that recognize extracellular components of pathogens, and TLR3, TLR7, TLR8, TLR9, and TLR13 are located on endosomes where they recognize foreign nucleic acids [2, 3]. As a member of the TLR family with less known functions, TLR13 can participate in the immune and inflammatory reactions for recognizing the conserved sequence of 23S rRNA in bacteria and induce immune response in mice [4, 5]. TLRs can recognize pathogen-related and structurally conserved molecules like single-stranded (ss) or double-stranded (ds) RNAs or DNAs, lipoproteins and lipopolysaccharides derived from microbes, and then activate immune cell responses to all externally attacking microbiota [2]. They participate in tumor immune surveillance and play different roles in tumor growth [6]. Activation of TLR4/9-COX2 signaling was involved in the metastasis of hepatocellular carcinoma. Inhibition of TLR4/9-COX2 signaling abrogated the neutrophils to form extracellular traps (NETs)-aroused metastatic potential [7].
The activation of TLRs downstream signal mainly depends on two types of transcription factors: NF-κB and interference regulatory factors (IRFs), which mainly induce the production of pro-inflammatory cytokines. In addition, it can induce the production of type I interferon (IFN) [2]. Activation of TLR7 and TLR8 triggers induction of a Th1-type innate immune response. The emergence of new structural and small molecule information generated in the last decade has contributed enormously to our understanding of this highly sophisticated process of innate immunity signaling with the recent developments in the small molecule activation of TLR7 and TLR8 [8].
Meanwhile, many studies have revealed that the expression levels of TLR7 and TLR8 are altered in some autoimmune diseases, such as arthritis, cancers [9,10,11,12,13], or in antiviral regimes, including coronavirus and human immunodeficiency virus(HIV) prevention [14]. TLR agonists have potential therapeutic prospects and are one of the research hotspots in the field of immunotherapy. Thus, novel drugs of TLR7 and TLR8 agonists with different scaffolds have been developed. These agonists can induce certain cytokines and chemokines that can be used as good adjuvants for vaccines in the treatment of some diseases. Furthermore, TLR7/8 agonists as potential therapeutics for tumor-targeted immunotherapy have been developed [8, 15, 16].
In this review, we summarize the frontiers of TLR 7 and 8 related research, especially, in the field of new drug development of TLR agonists for cancer immunotherapy.
TLR family and its expression patterns
A typical TLR is a single-spanning receptor consisting of three domains: an extracellular domain (ECD) for the recognition of pathogen-associated molecular patterns (PAMPs), a transmembrane domain (TMD), and an intracellular Toll-interleukin 1 receptor (TIR) domain for initiating downstream signaling [17]. Each of these receptors has a unique antigen-recognizing domain [18]. TLR3, TLR7, TLR8, and TLR9 act as sensors of nucleic acids. Specifically, TLR3 recognizes viral dsRNA, and TLR9 senses unmethylated cytosine phosphate guanosine (CpG) containing DNA, whereas TLR7 and TLR8 function as viral ssRNA sensors [19]. TLR4 identifies bacterial lipopolysaccharide (LPS) found in gram-negative bacteria, whereas TLR5 recognizes flagellin, and TLR9 subfamily members (TLR7, TLR8, and TLR9) recognize microbial DNA and RNA [18]. TLR10 is the latest discovered human TLR, and its ligands are still unknown (Fig. 1). However, TLR10 is the only known member of the TLR family that can elicit an anti-inflammatory effect [3]. The intracellular TLRs (TLR3, TLR7, TLR8, and TLR9 in human) can detect viral and bacterial nucleic acids, playing an important role in host immune response [20,21,22,23,24,25] and potentially in the treatment of cancer [26].
TLRs and their ligands. TLR1–7 and TLR9 have been characterized to recognize microbial components. TLR3 is essential for the recognition of microbial lipopeptides. TLR1 and TL6 associate with TLR2, and discriminate subtle differences between triacyl- and diacyl lipopeptides, respectively. TLR4 recognizes LPS. TLR9 is the CpG DNA receptor, whereas TLR3 is implicated in the recognition of viral dsRNA. TLR5 is a receptor for flagellin. TLR10 is the latest human TLR to be discovered and its function and ligands are still unclear
In contrast, extracellular TLRs, such as TLR1, TLR2, TLR4, TLR5, and TLR6, can be located at the plasma membrane where they recognize macromolecules exposed on the surface of pathogens [20,21,22,23,24,25]. Emerging evidence has suggested that dysfunction of TLRs has been correlated with inflammation associated with tumorigenesis (carcinogenesis), such as esophageal cancer [20] and other gastrointestinal tract cancers [27, 28]. Specifically, expression of TLR3, TLR4, TLR5, and TLR9 has been suggested as a potential mediator of the progression from reflux disorders to esophageal adenocarcinoma [29] Meanwhile, the increased expression levels of TLR3, TLR4, and TLR9 have been observed in esophageal squamous cell carcinoma (SCC) associated with lymphatic metastasis, with increased expression of TLR7 and TLR9 associating with advanced disease [30]. TLRs’ expression may be used as a valuable diagnostic or prognostic factor for esophageal cancer [20] .
TLR7, TLR8, and TLR9 display similarities in structure and endosomal localization, and natural agonists composed of nucleic acids, such as ssRNA or DNA with CpG motifs, activate the innate immune cells through these TLRs. The modulation of TLR7 and TLR8 responses is independent of CpG motifs or the nature of the oligodeoxynucleotides (ODNs) backbone structure, and the crosstalk between ODNs, IRMs, and TLR7 and TLR8 may be used for different clinical implications, including tumor therapy [31].
Although TLR7 and TLR8 show a high degree of sequence homology and similar structure, their biological responses to small molecule binding are very different. A recent study on molecular dynamics simulations reveals the selectivity mechanism of structurally similar agonists to TLR7 and TLR8, each with their own specific adapter proteins [32, 33]. While TLR7 is mainly expressed in antigen-presenting cells (APCs), such as plasmacytoid dendritic cells (pDCs) and B-cells, TLR8 is primarily expressed in myeloid cells, such as monocytes, macrophages, and myeloid dendritic cells [33]. Furthermore, TLR8 is considered biologically inactive in mice because they are unresponsive to imidazoquinolines (TLR7/8 agonists) when TLR7 expression has been knocked down. Hence, murine TLR8 cannot be triggered by TLR7/8 agonists [62]. Analysis results of normalized gene expression and corresponding clinical data of patients with skin cutaneous melanoma demonstrated that TLR7 and 8 expressions correlated with the expression of immune biomarkers and positively predicted the clinical outcome of patients with melanoma [63]. Meanwhile, in a preclinical melanoma mouse model, the TLR7 agonist IMQ improves T and NK cell function during BRAF-targeted therapy [64]. The topical application of TLR7 agonist IMQ in combination with other drugs, such as ipilimumab, for patients with malignant melanoma has been reported with successful results [65, 66].
Non-small cell lung cancer (NSCLC)
The gene expression analysis on a total of 33 advanced NSCLC patients treated with immune checkpoint inhibitors (ICI) evaluating the expression levels of 365 immune-related genes showed that high TLR7 expression levels were significantly associated with a lack of response to immunotherapy and the multivariate analysis confirmed TLR7 RNA expression as an independent predictor for both poorPFS and overall survival (OS) in advanced NSCLC patients treated with immunotherapy [67]. Furthermore, TLR7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid-derived suppressor cells in NSCLC [68]. A preclinical study showed that TLR7 agonists inhibit the growth and metastasis of lung cancer cells through immune activated mesenchymal stem cells [69]. Another study showed that R848-based stimulation of APCs in the tumor microenvironment resulted in the mobilization of an antitumor CD8+ immune response for treating metastatic NSCLC [70]. In addition, the TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer [71]. Although many studies have demonstrated that TLR7 agonists can enhance anti-tumor immune responses, these agonists also stimulate TLR7-expressing tumor cells. High TLR7 expression in the primary tumor confers poor clinical outcome and resistance to chemotherapy in lung cancer patients. This pro-tumorigenic effect of TLR7 has been validated in murine models of lung carcinoma [72].
Stomach adenocarcinoma.
A study in 30 patients with gastric cancer showed that the mRNA and protein expression levels of TLR7 were significantly downregulated in gastric cancer tissues. IMQ significantly increased TLR7 protein expression levels in SGC-7901 cells and promoted the secretion of proinflammatory cytokines such as TNF and IL-6 [73].
Overexpression of TLR7 in patients with advanced stomach adenocarcinoma (STAD) indicates a higher degree and poorer prognosis. In addition, TLR7 expression was positively correlated with immune cell infiltration and immune checkpoint expression. Therefore, TLR7 can be used as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma [74]. Conjugation of TLR7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects [75] and have synergistic antitumor effects with 5-fluorouracil via T cell activation and MDSCs inhibition [57, 76].
Other types of cancer
A meta-analysis of the prognostic role of TLRs in cancer showed that higher expression levels of TLR7 in tumor tissues could predict poorer survival, suggesting the expression level of TLR7 in cancerous tissue may have a prognostic value in patients with various cancers [181,182]. So far, there has been no breakthrough in the research of innate immune drugs regarding TLRs, and the selectivity and effectiveness are not clear yet. Emerging immunotherapies were proposed to overcome the primary and secondary resistance to existing immune checkpoint inhibitors, activate effector cells, and target immunosuppressive mechanisms in tumor microenvironment [141, 183,184,185]. More research needs to be explored regarding the mechanisms of the innate immune therapeutic agents. Autophagy pathway to inflammasome activation may influence the outcome of pro-tumor or anti-tumor responses depending on the cancer types, microenvironment, and the disease stage. Targeting macrophage approaches for either autophagy or inflammasome may be potential as anti-cancer strategies [186, 187].
Immunotherapy targeting inhibitory molecules like anti-CTLA-4 and anti-PD-1/PD-L1 were developed to overcome the immunosuppressive effects. These agents have demonstrated remarkable, durable responses in a small subset of patients [84]. TLRs agonists in combination of these inhibitory molecules and focus on the microenvironment and metabolic characteristics of tumor cells as well as the regulatory immune cells should be further explored [188]. Although no drug targeting TLR7/8 has been approved for cancer immunotherapy clinical application worldwide, but great efforts of global research and development have been made by focusing on TLR7/8-targeted agents for cancer immunotherapy and other types of diseases, such as patients with chronic hepatitis B. TLR agonists is considered a promising therapeutic strategy in the immunotherapy of solid tumors [189].
Clinical applications with a special subclass of patients may need to be categorized with either TLR agonist alone or agonist in combination with ICBs to specifically target that special population for cancer target immunotherapy, before it could be applied to a broad range of clinical applications. With the optimal antitumor immunity for robust enhancement of the effector T-cell response induced by tumor antigenic peptides and control or elimination of Treg cell-suppressive function, the combination of immune check point inhibitors with TLR agonists, in particular, the TLR8 agonist, may greatly improve the therapeutic potential of cancer immunotherapy. Furthermore, more novel targeting agents also need to be explored. We believe that with the continuous progress of research, the new TLR7/8 targeted drugs will improve the treatment efficiency and survival rate of patients with malignant tumors and benefit more patients.
Availability of data and materials
All clinical trials related information was obtained from public databases.
Change history
21 December 2022
A Correction to this paper has been published: https://doi.org/10.1186/s40364-022-00445-6
Abbreviations
- ADCC:
-
Antibody-dependent cell-mediated cytotoxicity
- ALL:
-
Acute lymphocytic leukemia
- AML:
-
Acute myeloid leukemia
- APCs:
-
Antigen-presenting cells
- CHB:
-
Chronic hepatitis B
- CIN2:
-
Intra-epithelial neoplasia
- CpG:
-
Cytosine phosphate guanosine
- CRC:
-
Colorectal cancer
- CRP:
-
C-reactive protein
- cSCC:
-
Cutaneous squamous cell carcinoma
- dsDNA:
-
Double-stranded DNA
- ECD:
-
Extracellular domain
- HBV:
-
Hepatitis B virus
- HG:
-
High-grade
- HIV:
-
Human immunodeficiency virus
- HL:
-
Hodgkin lymphoma
- HPSCs:
-
Hematopoietic stem/progenitor cells
- HPV:
-
Human papillomavirus
- ICBs:
-
Immune checkpoint blockades
- ICC:
-
Intrahepatic cholangiocarcinoma
- ICI:
-
Immune checkpoint inhibitors
- IFN:
-
Interferon
- IMQ:
-
Imiquimod
- IRAK:
-
IL-1 receptor-associated kinase
- IRF:
-
Interferon regulatory factor
- IRFs:
-
Interference regulatory factors
- LAG3:
-
Lymphocyte activating gene 3
- LG:
-
Low-grade
- LPS:
-
Lipopolysaccharide
- LRR:
-
Leucine-rich region
- mAbs:
-
Monoclonal antibody
- mDCs:
-
Monocyte-derived dendritic cells
- MDSCs:
-
Myeloid-derived suppressor cells
- MIBC:
-
Muscle-invasive bladder cancer
- MM:
-
Multiple myeloma
- MPLA:
-
Monophosphoryl lipid A
- MyD88:
-
Myeloid differentiation factor 88
- NETs:
-
Neutrophils to form extracellular traps
- NF-kB:
-
Nuclear factor kappa-light-chain-enhancer of activated B cells
- NHL:
-
Non-Hodgkin lymphoma
- NMIBC:
-
Non-muscle invasive bladder cancer
- NPC:
-
Nasopharyngeal carcinoma
- NSCLC:
-
Non-small cell lung cancer
- ODNs:
-
Oligodeoxynucleotides
- OS:
-
Overall survival
- OSCC:
-
Oral squamous cell carcinoma
- PAMPs:
-
Pathogen-associated molecular patterns
- PD:
-
Pharmacokinetics
- PDAC:
-
Pancreatic ductal adenocarcinoma
- pDCs:
-
Plasmacytoid dendritic cells
- PDT:
-
Photodynamic therapy
- PFS:
-
Progression free survival
- PK:
-
Pharmacokinetics
- PLD:
-
Pegylated liposomal doxorubicin
- ssDNA:
-
Single-stranded DNA
- STAD:
-
Stomach adenocarcinoma
- TAMs:
-
Tumor-associated macrophages
- TCCs:
-
Transitional cell carcinomas
- TCR:
-
T-cell receptor
- TFH:
-
Targeting follicular helper T cells
- TIGIT:
-
T-cell immunoreceptor with Ig and ITIM domains
- TIL:
-
Tumor infiltrating lymphocytes
- TIR:
-
Toll-interleukin 1 receptor
- TLR:
-
Toll-like receptors
- TMD:
-
Transmembrane domain
- TRAF:
-
Tumor necrosis factor receptor-associated factor
- Treg:
-
Regulatory T cells
References
Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34(5):637–50.
Urban-Wojciuk Z, Khan MM, Oyler BL, Fåhraeus R, Marek-Trzonkowska N, Nita-Lazar A, et al. The role of TLRs in anti-cancer immunity and tumor rejection. Front Immunol. 2019;10:2388.
Fore F, Budipranama M, Destiawan RA. TLR10 and its role in immunity. Handb Exp Pharmacol. 2022;276:161–74.
Liu Y, Yang M, Tang X, Xu D, Chi C, Lv Z, et al. Characterization of a novel toll-like receptor 13 homologue from a marine fish Nibea albiflora, revealing its immunologic function as PRRs. Dev Comp Immunol. 2022;104563.
Kumar V. Toll-like receptors in adaptive immunity. Handb Exp Pharmacol. 2022;276:95–131.
Nouri Y, Weinkove R, Perret R. T-cell intrinsic toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells. J Immunother Cancer. 2021;9(11).
Yang LY, Luo Q, Lu L, Zhu WW, Sun HT, Wei R, et al. Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response. J Hematol Oncol. 2020;13(1):3.
McGowan DC. Latest advances in small molecule TLR 7/8 agonist drug research. Curr Top Med Chem. 2019;19(24):2228–38.
Sacre S, Lo A, Gregory B, Stephens M, Chamberlain G, Stott P, et al. Oligodeoxynucleotide inhibition of toll-like receptors 3, 7, 8, and 9 suppresses cytokine production in a human rheumatoid arthritis model. Eur J Immunol. 2016;46(3):772–81.
Brentano F, Kyburz D, Gay S. Toll-like receptors and rheumatoid arthritis. Methods Mol Biol. 2009;517:329–43.
Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen FH, et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 2005;52(8):2313–22.
Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17(32):3745–51.
Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R, et al. Up-regulated expression of toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol. 2008;152(3):482–7.
Patel MC, Shirey KA, Pletneva LM, Boukhvalova MS, Garzino-Demo A, Vogel SN, et al. Novel drugs targeting toll-like receptors for antiviral therapy. Futur Virol. 2014;9(9):811–29.
Patinote C, Karroum NB, Moarbess G, Cirnat N, Kassab I, Bonnet PA, et al. Agonist and antagonist ligands of toll-like receptors 7 and 8: ingenious tools for therapeutic purposes. Eur J Med Chem. 2020;193:112238.
Agrawal S, Kandimalla ER. Synthetic agonists of toll-like receptors 7, 8 and 9. Biochem Soc Trans. 2007;35(Pt 6):1461–7.
Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of toll-like receptor signalling complexes. Nat Rev Immunol. 2014;14(8):546–58.
Kauppila JH, Takala H, Selander KS, Lehenkari PP, Saarnio J, Karttunen TJ. Increased toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma. Histopathology. 2011;59(4):643–9.
Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461.
Davakis S, Kapelouzou A, Liakakos T, Mpoura M, Stergiou D, Sakellariou S, et al. The role of toll-like receptors in esophageal Cancer. Anticancer Res. 2022;42(6):2813–8.
Ioannou S, Voulgarelis M. Toll-like receptors, tissue injury, and tumourigenesis. Mediat Inflamm. 2010;2010.
Jiang S, Tanji H, Yin K, Zhang S, Sakaniwa K, Huang J, et al. Rationally designed small-molecule inhibitors targeting an unconventional pocket on the TLR8 protein-protein Interface. J Med Chem. 2020;63(8):4117–32.
Khan AA, Khan Z, Warnakulasuriya S. Cancer-associated toll-like receptor modulation and insinuation in infection susceptibility: association or coincidence? Ann Oncol. 2016;27(6):984–97.
Lee CC, Avalos AM, Ploegh HL. Accessory molecules for toll-like receptors and their function. Nat Rev Immunol. 2012;12(3):168–79.
Zaidi AH, Kelly LA, Kreft RE, Barlek M, Omstead AN, Matsui D, et al. Associations of microbiota and toll-like receptor signaling pathway in esophageal adenocarcinoma. BMC Cancer. 2016;16:52.
Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res. 2007;13(18 Pt 1):5280–9.
Baghdadi J, Chaudhary N, Pei Z, Yang L. Microbiome, innate immunity, and esophageal adenocarcinoma. Clin Lab Med. 2014;34(4):721–32.
Fukata M, Abreu MT. Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol. 2009;9(6):680–7.
Wells JM, Rossi O, Meijerink M, van Baarlen P. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4607–14.
Diakowska D, Nienartowicz M, Grabowski K, Rosińczuk J, Krzystek-Korpacka M. Toll-like receptors TLR-2, TLR-4, TLR-7, and TLR-9 in tumor tissue and serum of the patients with esophageal squamous cell carcinoma and gastro-esophageal junction cancer. Adv Clin Exp Med. 2019;28(4):515–22.
Gorden KK, Qiu X, Battiste JJ, Wightman PP, Vasilakos JP, Alkan SS. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J Immunol (Baltimore, Md : 1950). 2006;177(11):8164–70.
Wang X, Chen Y, Zhang S, Deng JN. Molecular dynamics simulations reveal the selectivity mechanism of structurally similar agonists to TLR7 and TLR8. PLoS One. 2022;17(4):e0260565.
Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol. 2002;3(6):499.
Liu J, Xu C, Hsu LC, Luo Y, **ang R, Chuang TH. A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition. Mol Immunol. 2010;47(5):1083–90.
de Marcken M, Dhaliwal K, Danielsen AC, Gautron AS, Dominguez-Villar M. TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection. Sci Signal. 2019;12(605).
Awasthi S. Toll-like receptor-4 modulation for cancer immunotherapy. Front Immunol. 2014;5:328.
Liu X, Li L, Peng G. TLR8 reprograms human Treg metabolism and function. Aging. 2019;11(17):6614–5.
Li L, Liu X, Sanders KL, Edwards JL, Ye J, Si F, et al. TLR8-mediated metabolic control of human Treg function: a mechanistic target for Cancer immunotherapy. Cell Metab. 2019;29(1):103–23.e5.
Xu R, Wu M, Liu S, Shang W, Li R, Xu J, et al. Glucose metabolism characteristics and TLR8-mediated metabolic control of CD4(+) Treg cells in ovarian cancer cells microenvironment. Cell Death Dis. 2021;12(1):22.
Cheng Y, Borcherding N, Ogunsakin A, Lemke-Miltner CD, Gibson-Corley KN, Rajan A, et al. The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent. Sci Rep. 2021;11(1):1535.
Dietsch GN, Lu H, Yang Y, Morishima C, Chow LQ, Disis ML, et al. Coordinated activation of toll-like Receptor8 (TLR8) and NLRP3 by the TLR8 agonist, VTX-2337, ignites Tumoricidal natural killer cell activity. PLoS One. 2016;11(2):e0148764.
Khanna V, Kim H, Zhang W, Larson P, Shah M, Griffith TS, et al. Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). Sci Rep. 2021;11(1):3346.
Tanji H, Ohto U, Shibata T, Miyake K, Shimizu T. Structural reorganization of the toll-like receptor 8 dimer induced by agonistic ligands. Science. 2013;339(6126):1426–9.
Wang Z, Gao Y, He L, Sun S, **a T, Hu L, et al. Structure-based Design of Highly Potent Toll-like Receptor 7/8 dual agonists for Cancer immunotherapy. J Med Chem. 2021;64(11):7507–32.
Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrié M, et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol. 2010;12(4):401–8.
Weigel BJ, Cooley S, DeFor T, Weisdorf DJ, Panoskaltsis-Mortari A, Chen W, et al. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. Am J Hematol. 2012;87(10):953–6.
Cen X, Liu S, Cheng K. The role of toll-like receptor in inflammation and tumor immunity. Front Pharmacol. 2018;9:878.
Nurmi AM, Hagström J, Mustonen H, Seppänen H, Haglund C. The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvant therapy. PLoS One. 2022;17(5):e0267792.
Grimmig T, Matthes N, Hoeland K, Tripathi S, Chandraker A, Grimm M, et al. TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. Int J Oncol. 2015;47(3):857–66.
Michaelis KA, Norgard MA, Zhu X, Levasseur PR, Sivagnanam S, Liudahl SM, et al. The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nat Commun. 2019;10(1):4682.
Lanki M, Seppänen H, Mustonen H, Hagström J, Haglund C. Toll-like receptor 1 predicts favorable prognosis in pancreatic cancer. PLoS One. 2019;14(7):e0219245.
Beilmann-Lehtonen I, Hagström J, Kaprio T, Stenman UH, Strigård K, Palmqvist R, et al. The relationship between the tissue expression of TLR2, TLR4, TLR5, and TLR7 and systemic inflammatory responses in colorectal Cancer patients. Oncology. 2021;99(12):790–801.
Beilmann-Lehtonen I, Hagström J, Mustonen H, Koskensalo S, Haglund C, Böckelman C. High tissue TLR5 expression predicts better outcomes in colorectal Cancer patients. Oncology. 2021;99(9):589–600.
Hong EH, Cho J, Ahn JH, Kwon BE, Kweon MN, Seo SU, et al. Plasmacytoid dendritic cells regulate colitis-associated tumorigenesis by controlling myeloid-derived suppressor cell infiltration. Cancer Lett. 2020;493:102–12.
Lin X, Zhang J, Wang X, Lin G, Chen T. Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer. Anti-Cancer Drugs. 2020;31(10):989–96.
Yu S, Ren X, Li L. Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin. Exp Hematol Oncol. 2022;11(1):43.
Hao Z, Li R, Wang Y, Li S, Hong Z, Han Z. Landscape of myeloid-derived suppressor cell in tumor immunotherapy. Biomark Res. 2021;9(1):77.
Liu Z, **e Y, **ong Y, Liu S, Qiu C, Zhu Z, et al. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages. Cancer Lett. 2020;469:173–85.
Pilch Z, Tonecka K, Braniewska A, Sas Z, Skorzynski M, Boon L, et al. Antitumor activity of TLR7 is potentiated by CD200R antibody leading to changes in the tumor microenvironment. Cancer Immunol Res. 2018;6(8):930–40.
Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, et al. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer. 2017;141(6):1222–30.
Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, et al. Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy. Oncotarget. 2016;7(13):17035–46.
Thomas G, Micci L, Yang W, Katakowski J, Oderup C, Sundar P, et al. Intra-Tumoral activation of endosomal TLR pathways reveals a distinct role for TLR3 agonist dependent Type-1 interferons in sha** the tumor immune microenvironment. Front Oncol. 2021;11:711673.
Zhang M, Yan Z, Wang J, Yao X. Toll-like receptors 7 and 8 expression correlates with the expression of immune biomarkers and positively predicts the clinical outcome of patients with melanoma. Onco Targets Ther. 2017;10:4339–46.
Bellmann L, Cappellano G, Schachtl-Riess JF, Prokopi A, Seretis A, Ortner D, et al. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model. Int J Cancer. 2020;146(5):1409–20.
Verga E, Chohan B, Verdolini R. Malignant melanoma treated with topical Imiquimod: a bespoke treatment that spared the amputation. Case Rep Dermatol 2019;11(1):1–6.
Joseph RW, Cappel M, Tzou K, Bagaria S, Gilstrap C, Swaika A, et al. Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod. Melanoma Res. 2016;26(4):409–12.
Baglivo S, Bianconi F, Metro G, Gili A, Tofanetti FR, Bellezza G, et al. Higher TLR7 gene expression predicts poor clinical outcome in advanced NSCLC patients treated with immunotherapy. Genes. 2021;12(7).
Dajon M, Iribarren K, Petitprez F, Marmier S, Lupo A, Gillard M, et al. Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells. Oncoimmunology. 2019;8(1):e1505174.
Ye H, Pan J, Gong E, Cai X, Xu C, Li Y, et al. Inhibitory effect of immunologically activated mesenchymal stem cells on lung Cancer cell growth and metastasis. Cancer Biother Radiopharm. 2021.
Vinod N, Hwang D, Azam SH, Van Swearingen AED, Wayne E, Fussell SC, et al. High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. Sci Adv. 2020;6(25):eaba5542.
Zhou J, Xu Y, Wang G, Mei T, Yang H, Liu Y. The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer. Int J Oncol. 2022;61(1).
Dajon M, Iribarren K, Cremer I. Dual roles of TLR7 in the lung cancer microenvironment. Oncoimmunology. 2015;4(3):e991615.
Jiang J, Dong L, Qin B, Shi H, Guo X, Wang Y. Decreased expression of TLR7 in gastric cancer tissues and the effects of TLR7 activation on gastric cancer cells. Oncol Lett. 2016;12(1):631–6.
Yuan Q, Zhou Q, Ren J, Wang G, Yin C, Shang D, et al. WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma. Cancer Med. 2021;10(12):4004–16.
Wang XD, Gao NN, Diao YW, Liu Y, Gao D, Li W, et al. Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-ag exerts antitumor effects. World J Gastroenterol. 2015;21(26):8052–60.
Wang X, Liu Y, Diao Y, Gao N, Wan Y, Zhong J, et al. Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil. J Transl Med. 2018;16(1):120.
Wang Q, Zhang X, **ao T, Pan C, Liu X, Zhao Y. Prognostic role of toll-like receptors in cancer: a meta-analysis. Ther Clin Risk Manag. 2018;14:1323–30.
Mohamed FEZ, Jalan R, Minogue S, Andreola F, Habtesion A, Hall A, et al. Inhibition of TLR7 and TLR9 reduces human Cholangiocarcinoma cell proliferation and tumor development. Dig Dis Sci. 2022;67(5):1806–21.
Safarzadeh E, Mohammadi A, Mansoori B, Duijf PHG, Hashemzadeh S, Khaze V, et al. STAT3 silencing and TLR7/8 pathway activation repolarize and suppress myeloid-derived suppressor cells from breast Cancer patients. Front Immunol. 2020;11:613215.
Economopoulou P, Koutsodontis G, Strati A, Kirodimos E, Giotakis E, Maragoudakis P, et al. Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC). Oral Oncol. 2019;94:93–100.
Haeggblom L, Näsman A, Ramqvist T, Haglund C, Hagström J, Mäkitie A, et al. TLR5 and TLR7 are differentially expressed in human papillomavirus-positive and negative base of tongue squamous cell carcinoma, and TLR7 may have an independent prognostic influence. Acta Otolaryngol. 2019;139(2):206–10.
Vlad C, Dina C, Kubelac P, Vlad D, Pop B, Achimas CP. Expression of toll-like receptors in ovarian cancer. J BUON. 2018;23(6):1725–31.
Xun Y, Yang H, Kaminska B, You H. Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma. J Hematol Oncol. 2021;14(1):176.
Marin-Acevedo JA, Kimbrough EO, Manochakian R, Zhao Y, Lou Y. Immunotherapies targeting stimulatory pathways and beyond. J Hematol Oncol. 2021;14(1):78.
Ruuskanen M, Leivo I, Minn H, Vahlberg T, Haglund C, Hagström J, et al. Expression of toll-like receptors in non-endemic nasopharyngeal carcinoma. BMC Cancer. 2019;19(1):624.
Halec G, Scott ME, Farhat S, Darragh TM, Moscicki AB. Toll-like receptors: important immune checkpoints in the regression of cervical intra-epithelial neoplasia 2. Int J Cancer. 2018;143(11):2884–91.
Schary N, Novak B, Kämper L, Yousf A, Lübbert H. Identification and pharmacological modification of resistance mechanisms to protoporphyrin-mediated photodynamic therapy in human cutaneous squamous cell carcinoma cell lines. Photodiagn Photodyn Ther. 2022:103004.
Rolig AS, Rose DC, McGee GH, Rubas W, Kivimäe S, Redmond WL. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity over BEMPEG+RT. J Immunother Cancer. 2022;10(4).
Garau G, Rocca PC, Manca A, Madonia M, Siracusa G, Sotgiu G, et al. Preliminary study on the expression of toll-like receptors 7 and 8 in bladder urothelial tumors. Urologia. 2015;82(4):226–8.
Ni YH, Ding L, Zhang DY, Hou YY, Huang X, Hu Q. Distinct expression patterns of toll-like receptor 7 in tumour cells and fibroblast-like cells in oral squamous cell carcinoma. Histopathology. 2015;67(5):730–9.
Dajon M, Iribarren K, Cremer I. Toll-like receptor stimulation in cancer: a pro- and anti-tumor double-edged sword. Immunobiology. 2017;222(1):89–100.
Palumbo A Jr, Meireles Da Costa N, Pontes B, Leite de Oliveira F, Lohan Codeço M, Ribeiro Pinto LF, et al. Esophageal Cancer development: crucial clues arising from the extracellular matrix. Cells. 2020;9(2).
Takala H, Kauppila JH, Soini Y, Selander KS, Vuopala KS, Lehenkari PP, et al. Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun. 2011;3(6):631–8.
Wang L, Yu K, Zhang X, Yu S. Dual functional roles of the MyD88 signaling in colorectal cancer development. Biomed Pharmacother. 2018;107:177–84.
Wu K, Zhang H, Fu Y, Zhu Y, Kong L, Chen L, et al. TLR4/MyD88 signaling determines the metastatic potential of breast cancer cells. Mol Med Rep. 2018;18(3):3411–20.
Branchi V, Esser L, Boden C, Jafari A, Henn J, Lingohr P, et al. A combined TLR7/TLR9/GATA3 score can predict prognosis in biliary tract Cancer. Diagnostics (Basel). 2021;11(9).
Huang X, Zhang X, Lu M. Recent trends in the development of toll-like receptor 7/8-targeting therapeutics. Expert Opin Drug Discovery. 2021;16(8):869–80.
Vierbuchen T, Stein K, Heine H. RNA is taking its toll: impact of RNA-specific toll-like receptors on health and disease. Allergy. 2019;74(2):223–35.
Braunstein MJ, Kucharczyk J, Adams S. Targeting toll-like receptors for Cancer therapy. Target Oncol. 2018;13(5):583–98.
Li TT, Ogino S, Qian ZR. Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy. World J Gastroenterol. 2014;20(47):17699–708.
Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency. Clin Microbiol Rev. 2011;24(3):490–7.
Piras V, Selvarajoo K. Beyond MyD88 and TRIF pathways in toll-like receptor signaling. Front Immunol. 2014;5:70.
Zhu G, Cheng Z, Huang Y, Zheng W, Yang S, Lin C, et al. MyD88 mediates colorectal cancer cell proliferation, migration and invasion via NF-κB/AP-1 signaling pathway. Int J Mol Med. 2020;45(1):131–40.
Li X, Wang S, Zhu R, Li H, Han Q, Zhao RC. Lung tumor exosomes induce a pro-inflammatory phenotype in mesenchymal stem cells via NFκB-TLR signaling pathway. J Hematol Oncol. 2016;9(1):42.
Frega G, Wu Q, Le Naour J, Vacchelli E, Galluzzi L, Kroemer G, et al. Trial watch: experimental TLR7/TLR8 agonists for oncological indications. Oncoimmunology. 2020;9(1):1796002.
Ding R, Jiao A, Zhang B. Targeting toll-like receptors on T cells as a therapeutic strategy against tumors. Int Immunopharmacol. 2022;107:108708.
Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell. 2020;180(6):1044–66.
Akilesh HM, Buechler MB, Duggan JM, Hahn WO, Matta B, Sun X, et al. Chronic TLR7 and TLR9 signaling drives anemia via differentiation of specialized hemophagocytes. Science. 2019;363(6423):eaao5213.
Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol (Baltimore, Md : 1950). 2005;174(3):1259–68.
Kim H, Niu L, Larson P, Kucaba TA, Murphy KA, James BR, et al. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials. 2018;164:38–53.
Veneziani I, Alicata C, Pelosi A, Landolina N, Ricci B, D'Oria V, et al. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56(bright)CD16(−) subset. J Immunother Cancer. 2022;10(1).
Yin T, He S, Wang Y. Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model. Mol Med Rep. 2015;12(3):3515–20.
Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol (Baltimore, Md : 1950). 2005;175(3):1636–42.
Peng Y, Wang Y, Wang M, Lan J, Chen Y. Therapeutic applications of toll-like receptors (TLRs) agonists in AML. Clin Transl Oncol. 2022.
Rook AH, Gelfand JM, Wysocka M, Troxel AB, Benoit B, Surber C, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126(12):1452–61.
Killock D. Haematological cancer: Resiquimod—a topical CTCL therapy. Nat Rev Clin Oncol. 2015;12(10):563.
Koh J, Kim S, Lee SN, Kim SY, Kim JE, Lee KY, et al. Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. Nanomedicine. 2021;37:102415.
Li F, Zheng X, Wang X, Xu J, Zhang Q. Macrophage polarization synergizes with oxaliplatin in lung cancer immunotherapy via enhanced tumor cell phagocytosis. Transl Oncol. 2021;14(11):101202.
Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, et al. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol. 2006;18(7):1115–26.
Dou L, Meng X, Yang H, Dong H. Advances in technology and applications of nanoimmunotherapy for cancer. Biomark Res. 2021;9(1):63.
Tian H, Zhang T, Qin S, Huang Z, Zhou L, Shi J, et al. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J Hematol Oncol. 2022;15(1):132.
Kim H, Khanna V, Kucaba TA, Zhang W, Sehgal D, Ferguson DM, et al. TLR7/8 agonist-loaded nanoparticles augment NK cell-mediated antibody-based Cancer immunotherapy. Mol Pharm. 2020;17(6):2109–24.
Hung IF, Zhang AJ, To KK, Chan JF, Li P, Wong TL, et al. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-Centre, double-blind, randomised, controlled phase 2b/3 trial. Lancet Infect Dis. 2016;16(2):209–18.
Hung IF, Yap DY, Yip TP, Zhang RR, To KK, Chan KH, et al. A double-blind, randomized phase 2 controlled trial of intradermal hepatitis B vaccination with a topical toll-like receptor 7 agonist Imiquimod, in patients on Dialysis. Clin Infect Dis. 2021;73(2):e304–e11.
Li S, Yao JC, Li JT, Schmidt AP, Link DC. TLR7/8 agonist treatment induces an increase in bone marrow resident dendritic cells and hematopoietic progenitor expansion and mobilization. Exp Hematol. 2021;96:35–43.e7.
Chi H, Hao Y, Wang X, Tang L, Deng Y, Chen X, et al. A therapeutic whole-tumor-cell vaccine covalently conjugated with a TLR7 agonist. Cells. 2022;11(13).
Zhu J, He S, Du J, Wang Z, Li W, Chen X, et al. Local administration of a novel toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma. J Hematol Oncol. 2015;8(1):21.
Niu C, Li L, Daffis S, Lucifora J, Bonnin M, Maadadi S, et al. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism. J Hepatol. 2018;68(5):922–31.
Li L, Barry V, Daffis S, Niu C, Huntzicker E, French DM, et al. Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells. J Hepatol. 2018;68(5):912–21.
Menne S, Tumas DB, Liu KH, Thampi L, AlDeghaither D, Baldwin BH, et al. Sustained efficacy and seroconversion with the toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B. J Hepatol. 2015;62(6):1237–45.
Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, Giese T, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (Baltimore, Md : 1950). 2002;168(9):4531–7.
Dang Y, Rutnam ZJ, Dietsch G, Lu H, Yang Y, Hershberg R, et al. TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cells. J Leukoc Biol. 2018;103(1):157–64.
Lu H, Dietsch GN, Matthews MA, Yang Y, Ghanekar S, Inokuma M, et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res. 2012;18(2):499–509.
Dietsch GN, Randall TD, Gottardo R, Northfelt DW, Ramanathan RK, Cohen PA, et al. Late-stage Cancer patients remain highly responsive to immune activation by the selective TLR8 agonist Motolimod (VTX-2337). Clin Cancer Res. 2015;21(24):5445–52.
Wang Y, **ang Y, **n VW, Wang XW, Peng XC, Liu XQ, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020;13(1):107.
Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005;23:275–306.
Dalgaard J, Beckstrøm KJ, Jahnsen FL, Brinchmann JE. Differential capability for phagocytosis of apoptotic and necrotic leukemia cells by human peripheral blood dendritic cell subsets. J Leukoc Biol. 2005;77(5):689–98.
Serrano R, Wesch D, Kabelitz D. Activation of human γδ T cells: modulation by toll-like receptor 8 ligands and role of monocytes. Cells. 2020;9(3).
Kang Y, Flores L, Ngai HW, Cornejo YR, Haber T, McDonald M, et al. Large, anionic liposomes enable targeted intraperitoneal delivery of a TLR 7/8 agonist to repolarize ovarian Tumors' microenvironment. Bioconjug Chem. 2021;32(8):1581–92.
An Y, Yang Q. Tumor-associated macrophage-targeted therapeutics in ovarian cancer. Int J Cancer. 2021;149(1):21–30.
Zhu S, Yi M, Wu Y, Dong B, Wu K. Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Exp Hematol Oncol. 2021;10(1):60.
Qiu Y, Chen T, Hu R, Zhu R, Li C, Ruan Y, et al. Next frontier in tumor immunotherapy: macrophage-mediated immune evasion. Biomark Res. 2021;9(1):72.
Xu T, Yu S, Zhang J, Wu S. Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers. J Hematol Oncol. 2021;14(1):181.
Xu J, Guo R, Jia J, He Y, He S. Activation of toll-like receptor 2 enhances peripheral and tumor-infiltrating CD8(+) T cell cytotoxicity in patients with gastric cancer. BMC Immunol. 2021;22(1):67.
Wu W, Liu Y, Zeng S, Han Y, Shen H. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes. J Hematol Oncol. 2021;14(1):160.
Zhang C, Ding H, Huang H, Palashati H, Miao Y, **ong H, et al. TCR repertoire intratumor heterogeneity of CD4(+) and CD8(+) T cells in centers and margins of localized lung adenocarcinomas. Int J Cancer. 2019;144(4):818–27.
Zhang Q, Lou Y, Yang J, Wang J, Feng J, Zhao Y, et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut. 2019;68(11):2019–31.
Liu YY, Yang QF, Yang JS, Cao RB, Liang JY, Liu YT, et al. Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer. Int J Cancer. 2019;145(5):1423–31.
Zhang Y, Zhu Y, Wang J, Xu Y, Wang Z, Liu Y, et al. A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma. Cancer Immunol Immunother. 2022;71(3):675–88.
Guo L, Bi X, Li Y, Wen L, Zhang W, Jiang W, et al. Characteristics, dynamic changes, and prognostic significance of TCR repertoire profiling in patients with renal cell carcinoma. J Pathol. 2020;251(1):26–37.
Song Y, Xu M, Li Y, Li Y, Gu W, Halimu G, et al. An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy. Int J Pharm. 2020;586:119498.
Wang Y, Yang H, Li H, Zhao S, Zeng Y, Zhang P, et al. Development of a novel TLR8 agonist for cancer immunotherapy. Mol Biomed. 2020;1(1):6.
Zou X, Guo B, Ling Q, Mo Z. Toll-like receptors serve as biomarkers for early diagnosis and prognosis assessment of kidney renal clear cell carcinoma by influencing the immune microenvironment: comprehensive bioinformatics analysis combined with experimental validation. Front Mol Biosci. 2022;9:832238.
Yang L, Zhang Y. Tumor-associated macrophages, potential targets for cancer treatment. Biomark Res. 2017;5(1):25.
Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14(1):156.
Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.
Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013;93(6):847–63.
Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res. 2012;35(8):1297–316.
Chatterjee S, Crozet L, Damotte D, Iribarren K, Schramm C, Alifano M, et al. TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. Cancer Res. 2014;74(18):5008–18.
Ochi A, Graffeo CS, Zambirinis CP, Rehman A, Hackman M, Fallon N, et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest. 2012;122(11):4118–29.
Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, et al. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother. 2010;59(12):1877–84.
Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V, et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res. 2008;14(3):856–64.
Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, et al. Phase Ib trial of the toll-like receptor 8 agonist, Motolimod (VTX-2337), combined with Cetuximab in patients with recurrent or metastatic SCCHN. Clin Cancer Res. 2017;23(10):2442–50.
Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, Bauman JE, et al. Phase Ib study of immune biomarker modulation with Neoadjuvant Cetuximab and TLR8 stimulation in head and neck Cancer to overcome suppressive myeloid signals. Clin Cancer Res. 2018;24(1):62–72.
Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, et al. Effect of adding Motolimod to standard combination chemotherapy and Cetuximab treatment of patients with squamous cell carcinoma of the head and neck: the Active8 randomized clinical trial. JAMA Oncol. 2018;4(11):1583–8.
Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother. 2009;58(9):1375–85.
Monk BJ, Facciabene A, Brady WE, Aghajanian CA, Fracasso PM, Walker JL, et al. Integrative development of a TLR8 agonist for ovarian Cancer Chemoimmunotherapy. Clin Cancer Res. 2017;23(8):1955–66.
Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, et al. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a gynecologic oncology group partners study. Ann Oncol. 2017;28(5):996–1004.
Mathé G, Amiel J, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, et al. Active immunotherapy for acute lymphoblastic leukaemia. Lancet. 1969;293(7597):697–9.
Deng G, Ge J, Liu C, Pang J, Huang Z, Peng J, et al. Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy. Clin Res Hepatol Gastroenterol. 2017;41(4):386–98.
Mackman RL, Mish M, Chin G, Perry JK, Appleby T, Aktoudianakis V, et al. Discovery of GS-9688 (Selgantolimod) as a potent and selective Oral toll-like receptor 8 agonist for the treatment of chronic hepatitis B. J Med Chem. 2020;63(18):10188–203.
Ayithan N, Tang L, Tan SK, Chen D, Wallin JJ, Fletcher SP, et al. Follicular helper T (T(FH)) cell targeting by TLR8 signaling for improving HBsAg-specific B cell response in chronic hepatitis B patients. Front Immunol. 2021;12:735913.
Gane EJ, Kim HJ, Visvanathan K, Kim YJ, Nguyen AH, Wallin JJ, et al. Safety, pharmacokinetics, and pharmacodynamics of the Oral TLR8 agonist Selgantolimod in chronic hepatitis B. Hepatology. 2021;74(4):1737–49.
Daffis S, Balsitis S, Chamberlain J, Zheng J, Santos R, Rowe W, et al. Toll-like receptor 8 agonist GS-9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B. Hepatology. 2021;73(1):53–67.
Ayithan N, Ghosh A, Dwivedi A, Wallin JJ, Tan SK, Chen D, et al. Oral selective TLR8 agonist Selgantolimod induces multiple immune cell responses in humans. Viruses. 2021;13(12).
Reyes M, Lutz JD, Lau AH, Gaggar A, Grant EP, Joshi A, et al. Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral toll-like receptor 8 agonist: a phase Ia study in healthy subjects. Antivir Ther. 2020;25(3):171–80.
Amin OE, Colbeck EJ, Daffis S, Khan S, Ramakrishnan D, Pattabiraman D, et al. Therapeutic potential of TLR8 agonist GS-9688 (Selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators. Hepatology. 2021;74(1):55–71.
Release. N. Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase I Clinical Trial of CB06. Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase I Clinical Trial of CB06.http://www.core-biopharma.com/news/54.html?l=en-us.
Annese T, Tamma R, Ribatti D. Update in TIGIT immune-checkpoint role in Cancer. Front Oncol. 2022;12:871085.
Chiang EY, Mellman I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer. 2022;10(4).
Agnihotri P, Mishra AK, Agarwal P, Vignali KM, Workman CJ, Vignali DAA, et al. Epitope map** of therapeutic antibodies targeting human LAG3. J Immunol (Baltimore, Md : 1950). 2022;209(8):1586–94.
Andrews LP, Cillo AR, Karapetyan L, Kirkwood JM, Workman CJ, Vignali DAA. Molecular pathways and mechanisms of LAG-3 in Cancer therapy. Clinical cancer research : an official journal of the American association for. Cancer Res. 2022.
Pan C, Liu H, Robins E, Song W, Liu D, Li Z, et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020;13(1):29.
Wang Y, Johnson KCC, Gatti-Mays ME, Li Z. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. J Hematol Oncol. 2022;15(1):118.
Yu W, Lei Q, Yang L, Qin G, Liu S, Wang D, et al. Contradictory roles of lipid metabolism in immune response within the tumor microenvironment. J Hematol Oncol. 2021;14(1):187.
Chung C, Seo W, Silwal P, Jo EK. Crosstalks between inflammasome and autophagy in cancer. J Hematol Oncol. 2020;13(1):100.
Li W, Wang F, Guo R, Bian Z, Song Y. Targeting macrophages in hematological malignancies: recent advances and future directions. J Hematol Oncol. 2022;15(1):110.
Yuan S, Liu Z, Xu Z, Liu J, Zhang J. High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies. J Hematol Oncol. 2020;13(1):91.
Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28.
Acknowledgments
Not Applicable.
Funding
This work was supported by the Project of Science and Technology Department of Henan Province, China (LHGJ20190039, SBGJ20202076, recipient JY), and Talent Research Fund of the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (recipient JY). The funding bodies did not participate in the study design, in data collection, analysis, and interpretation, and in writing the manuscript.
Author information
Authors and Affiliations
Contributions
J.Y., Y.S., and D.W. designed and directed the study, H.S., Y.L., and P. Z. wrote the manuscript draft. J.Y., H. X., Y.S., and D.W. reviewed the manuscript. S.Z. provided resources. All authors reviewed and approved the final manuscript.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not Applicable.
Competing interests
The authors declare no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Sun, H., Li, Y., Zhang, P. et al. Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives. Biomark Res 10, 89 (2022). https://doi.org/10.1186/s40364-022-00436-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s40364-022-00436-7